NXTM: NxStage Medical, Inc. - Summary | Jitta

NxStage Medical, Inc.

NASDAQ:NXTM

Notice
Stock data is unavailable or the company’s delisted.
Price
$30.00
Loss Chance
58.4%
3.30JITTA SCORE
96.14%Over Jitta Line
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (0)
Recent Business Performance (0)
Financial Strength (10)
Return to Shareholders (0)
Competitive Advantage (0)
Jitta Signs
Recent Business PerformanceEarning Growth Last Year
Revenue and EarningEarning loss detected in 2017
Operating MarginInconsistent
CapExVery High
Key Stats
Jitta Score
Jitta Line
3.30
96.14%
COMPANY DESCRIPTION
NxStage Medical, Inc., a medical technology company, develops, manufactures and markets products for the treatment of end-stage renal disease (ESRD) and acute kidney failure. It offers System One Cycle, a portable hemodialysis system, which is used primarily for home hemodialysis; PureFlow SL, offers water purification and dialysate production in one integrated unit, designed for use at home or in-center; chronic cartridges provides patient flexibility for more frequent, nocturnal, or intermittent renal replacement therapy at home; and Nx2me Connected Health, a telehealth platform for the collection and delivery of home hemodialysis treatment and patient medical information. It also offers bloodlines, needles, and dialysis fluids. The company provides dialysis services. It operates dialysis centers. NxStage Medical, Inc. was formerly known as QB Medical, Inc. The company was founded in 1998 and is based in Lawrence, Massachusetts. As of February 21, 2019, NxStage Medical, Inc. operates as a subsidiary of Fresenius Medical Care Holdings, Inc.